Bifogade filer
PDF
Kurs
+15,08%
Likviditet
0,69 MSEK
Kalender
| Est. tid* | ||
| 2026-02-11 | 10:30 | Bokslutskommuniké 2025 |
| 2025-11-12 | 08:30 | Kvartalsrapport 2025-Q3 |
| 2025-08-27 | 08:30 | Kvartalsrapport 2025-Q2 |
| 2025-05-30 | N/A | X-dag ordinarie utdelning QLIFE 0.00 SEK |
| 2025-05-28 | N/A | Årsstämma |
| 2025-05-20 | 08:30 | Kvartalsrapport 2025-Q1 |
| 2025-03-21 | - | Extra Bolagsstämma 2025 |
| 2025-02-12 | - | Bokslutskommuniké 2024 |
| 2024-11-07 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-29 | - | Kvartalsrapport 2024-Q2 |
| 2024-07-30 | - | Split QLIFE 2000:1 |
| 2024-05-28 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-08 | - | X-dag ordinarie utdelning QLIFE 0.00 SEK |
| 2024-05-07 | - | Årsstämma |
| 2024-02-08 | - | Bokslutskommuniké 2023 |
| 2024-01-16 | - | Extra Bolagsstämma 2023 |
| 2023-11-13 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-17 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-26 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-05 | - | X-dag ordinarie utdelning QLIFE 0.00 SEK |
| 2023-05-04 | - | Årsstämma |
| 2023-03-24 | - | Extra Bolagsstämma 2022 |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-11-25 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-29 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-06 | - | X-dag ordinarie utdelning QLIFE 0.00 SEK |
| 2022-05-05 | - | Årsstämma |
| 2022-05-05 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-11-08 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-16 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-06 | - | X-dag ordinarie utdelning QLIFE 0.00 SEK |
| 2021-05-05 | - | Årsstämma |
| 2021-05-05 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2020-11-19 | - | Extra Bolagsstämma 2020 |
| 2020-11-18 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-18 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-22 | - | X-dag ordinarie utdelning QLIFE 0.00 SEK |
| 2020-05-20 | - | Årsstämma |
| 2020-05-20 | - | Kvartalsrapport 2020-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Together with a partner, Qlife's scientific team has now finalized the prioritized project of freeze-drying the CRP reagents in the Egoo capsules. Small, dried reagent beads instead of liquid reagents will facilitate both transport and room temperature storage of test capsules - making the Egoo platform more versatile which is essential for the home-use environment.
Qlife has been able to develop a small, freeze-dried bead that consist of the CRP reagents used in the Egoo CRP Capsule. Instantly frozen reagents which then are freeze-dried into spherical beads are used instead of liquid reagents. This makes the product stable and user friendly and does not require refrigerated transport and storage.
"The freeze-drying project has been a prioritized project since it is essential for making our test capsules available for home-use. Together with our project partner, we have completed the required steps of production validation of the freeze-dried reagents. The next and exciting step is to introduce Egoo CRP Capsule to the market as the first product in our Egoo portfolio to become available for home use", says Thomas Warthoe, CEO of Qlife.
New Egoo CRP Capsule Features:- Freeze-dried beads instead of fluids
- More stable and user-friendly capsules without specific storage requirements
- Shipped and stored at room temperature up to +40 Celsius
Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34